Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIOTTO: GA101-DHAP in Relapsed/Refractory DLBCL
NCT02374424Phase 2Terminated
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Nov 2014
- Primary completion
- Feb 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of obinutuzumab in diffuse large B-cell lymphoma (DLBCL), sponsored by Fondazione Italiana Linfomi. Started Nov 2014; status: terminated.
02
Drugs
obinutuzumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02374424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02374424.